- Home
- AVK vs CELC Comparison
AVK vs CELC Comparison
Compare AVK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- CELC
- Stock Information
- Founded
- AVK 2003
- CELC 2011
- Country
- AVK United States
- CELC United States
- Employees
- AVK N/A
- CELC N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- CELC Medical Specialities
- Sector
- AVK Finance
- CELC Health Care
- Exchange
- AVK Nasdaq
- CELC Nasdaq
- Market Cap
- AVK 545.2M
- CELC 440.0M
- IPO Year
- AVK N/A
- CELC 2017
- Fundamental
- Price
- AVK $12.27
- CELC $39.17
- Analyst Decision
- AVK
- CELC Strong Buy
- Analyst Count
- AVK 0
- CELC 6
- Target Price
- AVK N/A
- CELC $39.67
- AVG Volume (30 Days)
- AVK 112.9K
- CELC 2.3M
- Earning Date
- AVK 01-01-0001
- CELC 08-13-2025
- Dividend Yield
- AVK 11.85%
- CELC N/A
- EPS Growth
- AVK N/A
- CELC N/A
- EPS
- AVK N/A
- CELC N/A
- Revenue
- AVK N/A
- CELC N/A
- Revenue This Year
- AVK N/A
- CELC N/A
- Revenue Next Year
- AVK N/A
- CELC N/A
- P/E Ratio
- AVK N/A
- CELC N/A
- Revenue Growth
- AVK N/A
- CELC N/A
- 52 Week Low
- AVK $9.24
- CELC $7.58
- 52 Week High
- AVK $12.16
- CELC $46.42
- Technical
- Relative Strength Index (RSI)
- AVK 57.77
- CELC 91.51
- Support Level
- AVK $12.21
- CELC $34.30
- Resistance Level
- AVK $12.32
- CELC $46.42
- Average True Range (ATR)
- AVK 0.13
- CELC 2.27
- MACD
- AVK -0.02
- CELC 3.03
- Stochastic Oscillator
- AVK 76.74
- CELC 78.05
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.